Two alternatively spliced forms of the human protein tyrosine phosphatase TCPTP (T-cell protein tyrosine phosphatase) exist: a 48 kDa form that is targeted to the endoplasmic reticulum (TC48) and a shorter 45 kDa form that is targeted to the nucleus (TC45). In this study we have identified Ser-304 (Phe 301 -Asp-His-Ser 304 -Pro-Asn-Lys 307 ) as a major TCPTP phosphorylation site and demonstrate that TC45, but not TC48, is phosphorylated on this site in vivo. Phosphorylation of TC45 on Ser-304 was cell cycle-dependent, and increased as cells progressed from G 2 into mitosis, but subsided upon mitotic exit. Ser-304 phosphorylation was increased when cells were arrested in mitosis by microtubule poisons such as nocodazole, but remained unaltered when cells were arrested at the G 2 /M checkpoint by adriamycin. Phosphorylation of Ser-304 did not alter significantly the phosphatase activity or the protein stability of TC45, and had no apparent effect on TC45 localization. Ser-304 phosphorylation was ablated when cells were treated with the CDK (cyclindependent protein kinase) inhibitors roscovitine or SU9516, but remained unaltered when ERK1/2 activation was inhibited with the MEK (mitogen-activated protein kinase/extracellularsignal-regulated kinase kinase) inhibitor PD98059. In addition, recombinant CDKs, but not the Polo-like kinase Plk1, phosphorylated Ser-304 in vitro. Our studies identify Ser-304 as a major phosphorylation site in human TCPTP, and the TC45 variant as a novel mitotic CDK substrate.
INTRODUCTION
PTPs (protein tyrosine phosphatases) catalyse the dephosphorylation of tyrosine-phosphorylated proteins and regulate signalling events that control fundamental cellular processes, such as growth, proliferation, differentiation, migration and survival [1] . Although the human genome encodes approximately 100 PTP genes [1, 2] , many of these genes can be alternatively spliced to generate structurally distinct enzymes with different subcellular localizations [1] . It is becoming increasingly apparent that, for many signalling proteins, alternatively spliced gene products can have unique biological properties [3] . Hence the number of functionally distinct PTPs may be significantly greater than the number of PTP genes identified in the human genome.
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bipartite nuclear localization sequence [4, [7] [8] [9] [10] [11] . Despite TC45 having an apparent exclusively nuclear localization in resting cells, TC45 can shuttle between the nuclear and cytoplasmic environments [12] and gain access to cytoplasmic substrates, such as the EGF (epidermal growth factor) receptor [13, 14] , the insulin receptor [15] , the adaptor protein p52 Shc [14] and JAKs (Janus protein tyrosine kinases) [16] , thereby regulating mitogen/growth factor-and cytokine-induced signalling [13, 14, 16, 17] . To date, STATs (signal transducer and activators of transcription) such as STAT1 are the only known nuclear substrates for TC45 [18, 19] . TCPTP may also regulate the progression of cells through the G 1 phase of the cell cycle [20, 21] , but the molecular mechanism by which this occurs is not known.
Despite TC48 and TC45 having identical catalytic domains and recognizing common substrates, such as the EGF receptor [14] and the insulin receptor [15] , several lines of evidence indicate that the two phosphatases might also have distinct substrates and divergent cellular roles. Utilizing substrate-trapping mutants, we have shown previously that TC45, but not TC48, recognizes the tyrosine-phosphorylated adaptor protein p52
Shc as well as two other unidentified substrates in response to EGF stimulation [14] . Moreover, even though both phosphatases can dephosphorylate the EGF receptor in a cellular context, only TC45 suppresses EGF receptor-mediated protein kinase B/Akt signalling [13] , whereas others have reported that an overexpressed substrate-trapping mutant of TC48, but not TC45, suppresses tumour cell adhesion and anchorage-independent growth [22] . Taken together, such observations suggest that TC45 and TC48 can serve as functionally distinct PTPs in vivo.
In the present paper, we demonstrate for the first time that endogenous TC45, but not the endoplasmic reticulum-localized TC48, is phosphorylated on Ser-304. We report that Ser-304 phosphorylation occurs primarily during mitosis, and may be mediated by CDKs (cyclin-dependent protein kinases). Our studies suggest that the alternatively spliced forms of TCPTP may be phosphorylated differentially by CDKs in mitosis, and may thus have distinct roles in cellular division. The monoclonal anti-TCPTP antibody CF4 has been described previously [14] .
MATERIALS AND METHODS

Materials
Plasmid constructs
TC45-pMT2, TC45-pCG, pET-GST and pET-TC45 have been described previously [12, 23] . Two rounds of PCR were undertaken to generate the Ser-304 to Ala or Glu phosphorylation site mutants using recombinant Taq DNA polymerase (Invitrogen, Carlsbad, CA, U.S.A.). In the first round, TC45-pBluescript II KS [10] was used as a template to generate two overlapping PCR products encompassing the 5 and 3 ends of the TC45 cDNA. The PCR product encompassing the 3 end of the TC45 cDNA incorporated the mutation for converting Ser-304 into either Ala or Glu; 5 -end PCR products were generated using 5 -GGCTCCCC-TGCAGATGCCCACCACCATCGAGCGGGAG-3 and 5 -ATG-ATCAAAGGCAGGAGATAA-3 , and 3 -end PCR products were generated with 5 -CGCCGCCTCGAGTTAGGTGTCTGTCAA-TCTTGGCCT-3 and 5 -CCTGCCTTTGATCATGCTCCAAAC-AAAATAATGAC-3 (for mutating Ser-304 to Ala) or 5 -CCT-GCCTTTGATCATGAGCCAAACAAAATAATGAC-3 (for mutating Ser-304 to Glu). For the second round of PCR, a mixture (approx. 1:1 molar ratio) of the 5 -and 3 -end first-round PCR products was utilized as template to generate the full-length TC45 mutant cDNAs. The oligonucleotides incorporated a PstI site immediately 5 to the initiating codon (5 -GGCTCCCCTGCA-GATGCCCACCACCATCGAGCGGGAG-3 ) and a XhoI site immediately 3 to the terminating codon (5 -CGCCGCCTCGA-GTTAGGTGTCTGTCAATCTTGGCCT-3 ). PstI/Xho1-digested second-round PCR products were cloned into the same site of the mammalian expression vector pMT2. The TC45-S304A-pCG and TC45-S304E-pCG constructs were generated by PCR using Platinum Pfx DNA polymerase (Invitrogen) and the TC45-S304A-pMT2 and TC45-S304E-pMT2 constructs as templates respectively. The 5 oligonucleotide used was 5 -GGCTCCCACTAGTATGCCCACCACCATCGAG-CGGGAG-3 and the 3 oligonucleotide was 5 -CCCAGTCATG-GATCCTTAGGTGTCTGTCAATCTTGGCCT-3 . The oligonucleotides incorporated an SpeI site immediately 5 to the initiating codons and a BamHI site immediately 3 to the termination codons. The SpeI/BamHI-digested PCR product was cloned into the XbaI/BamHI site of the mammalian expression vector pCG.
pET-TC45(1-349) and pET-TC45(1-349)S304E bacterial expression constructs were generated by PCR using Platinum Pfx DNA polymerase and the TC45-pMT2 and TC45-S304E-pMT2 constructs as templates respectively. The 5 oligonucleotide used was 5 -GGCTCCCGGATCCATGCCCACCACCATCGA-GCGGGAG-3 , and incorporated a BamHI site immediately 5 of the initiating methionine; the 3 oligonucleotide was 5 -A-GCTTACTTAAGAATATCTCGTGAGAGTGACAAGAGGAG-3 , and incorporated a TAA stop codon followed by an EcoRI site immediately after the codon for residue 349. The PCR products were digested with BamHI/EcoRI and cloned into the same sites of pET-GST to generate pET-GST-TC45(1-349) and pET-GST-TC45(1-349)S304E. The NcoI/EcoRI fragment from pET-TC45 was then replaced with the same fragment from either pET-GST-TC45(1-349) or pET-GST-TC45(1-349)S304E to generate pET-TC45(1-349) and pET-TC45(1-349)S304E respectively.
The structures of all constructs generated were confirmed by restriction endonuclease analysis, and the fidelity of the cloned cDNAs was confirmed by sequencing.
Cell culture, transfections, cell-cycle synchronization and flow cytometry HEK (human embryonic kidney) 293, HeLa cervical adenocarcinoma, U2OS osteosarcoma, and monkey CV1 and COS1 cells were cultured at 37
• C and 5 % CO 2 in DMEM (Dulbecco's modified Eagle's medium) containing 10 % (v/v) FBS (fetal bovine serum), 100 units/ml penicillin and 100 µg/ml streptomycin. Where indicated, cells were serum-starved for 20-24 h in DMEM containing 0.1 % (v/v) FBS plus antibiotics. COS1 cells were transfected by the calcium phosphate precipitation method as described previously [14] , whereas HeLa cells were transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Where indicated, HEK293, CV1 and U2OS cells were electroporated at 975 mM and 200 V as described previously [13] . For cell cycle synchronization, cells were arrested in S-phase in the presence of 2 mM thymidine for 20 h and then washed with PBS and released in DMEM plus 10 % (v/v) FBS. To arrest cells in mitosis, cells were treated for 20 h with 100 ng/ml nocodazole. FACS was performed using propidium iodide-stained cells and a FACSCalibur flow cytometer (Becton Dickinson).
Metabolic labelling and TCPTP immunoprecipitation
COS1 cells were electroporated as described previously [13] with 20 µg of TC45-pMT2. At 36 h post-transfection, the cells were washed twice with phosphate-free DMEM and then incubated in phosphate-free DMEM for 60 min. Cells were labelled with 1.5 mCi of [ 32 P]P i per 10 cm dish for 5 h at 37
• C. Labelled cells were lysed in IP lysis buffer [50 mM Tris, pH 7.5, 1 % (w/v) Nonidet P-40, 150 mM NaCl, 50 mM NaF, leupeptin (5 µg/ml), pepstatin (1 µg/ml), 1 mM benzamidine and 2 mM PMSF] plus 1 µM okadaic acid, and precleared with 0.1 ml of Pansorbin for 30 min at 4
• C. Precleared lysates were centrifuged (12 000 g for 10 min at 4
• C), and TCPTP was immunoprecipitated from the supernatant with the monoclonal anti-TCPTP antibody CF4 as described previously [14] .
Reduction, alkylation, tryptic digestion, and phosphopeptide extraction and purification The 32 P-labelled immunoprecipitated TCPTP was resuspended in 3 × Laemmli sample buffer plus 10 mM DTT (dithiothreitol) and boiled for 5 min before being cooled to room temperature; acrylamide was then added to a final concentration of 1 % (w/v). Alkylation of the denatured and reduced TCPTP was allowed to proceed for 30 min at room temperature and the immunoprecipitates were resolved by SDS/PAGE. After staining with Coomassie Blue, the gel slice containing the immunoprecipitated TCPTP was destained, dried and then rehydrated in the presence of trypsin. Digestions were allowed to proceed overnight at 37
• C, and tryptic peptides were eluted with three sequential 30 min washes with 2 % (v/v) TFA (trifluoroacetic acid), 0.1 % TFA with 30 % (v/v) acetonitrile, and 0.1 % TFA with 60 % (v/v) acetonitrile, as described previously [24, 25] . The combined extracts were dried and desalted, and the phosphopeptides were either analysed by phosphopeptide mapping or separated by reverse-phase C18 chromatography (300 Å, 5 µm, 1 mm × 250 mm) using the Amersham Biosciences SMART system (60 min; linear 0-80 % acetonitrile gradient in 0.1 % TFA at 50 µl/min) for MALDI-TOF (matrix-assisted laser-desorption ionization-time-of-flight) MS analysis as described previously [24] [25] [26] . Fractions containing 32 P-labelled phosphopeptides were identified by Cerenkov counting. Phosphopeptides were separated in two dimensions on thin-layer cellulose plates by high-voltage electrophoresis at pH 1.9 [pH 1.9 buffer: 50 ml of formic acid (88 %, w/v), 156 ml of glacial acetic acid, and deionized water to 2 litres] in the first dimension and ascending phosphochromatography in the second dimension as described previously [24, 25] 32 P]phosphopeptides were sequenced on a Hewlett Packard G100A protein sequencer as described previously [24] , with extracted cycles diverted to a fraction collector and fractions spotted on to cellulose plates and quantified on a PhosphorImager using Image-Quant software.
Phosphoamino acid analysis [ 32 P]Phosphopeptides separated by phosphopeptide mapping were recovered from cellulose in pH 1.9 buffer and hydrolysed in 5.7 M HCl at 110
• C for 60 min. 32 P-labelled phosphoamino acids were dried and resuspended in pH 1.9 buffer, and then separated on thin-layer cellulose plates by high-voltage electrophoresis at pH 3.5 with internal phosphoamino acid standards as described previously [26] .
MALDI-TOF MS
Tryptic peptides were spotted on to the sample stage with α-cyano-4-hydroxycinnamic acid, and masses were analysed using a linear Voyager DE (PerSeptive Biosystems) MALDI-TOF instrument running in delayed extraction mode.
SDS/PAGE and immunoblotting
Unless otherwise indicated, proteins were resolved on 7.3 cm long SDS/PAGE (10 % polyacrylamide) gels using the Laemmli discontinuous buffer system [27] and the Bio-Rad (Hercules, CA, U.S.A.) Mini-PROTEAN ® II electrophoresis unit according to the manufacturer's instructions. For resolving the dephosphorylated and Ser-304 phosphorylated forms of TC45, proteins were resolved on 16 cm long SDS/PAGE (10 %) gels using the BioRad Protean II electrophoresis unit; proteins were electrophoresed until the 50 kDa protein standard (Bio-Rad Precision Protein Standards, prestained) was approx. 2 cm from the bottom of the gel. Resolved proteins were transferred on to an Immobilon TM -P transfer membrane (Millipore) using a Bio-Rad Trans-Blot SD semi-dry electrophoretic transfer apparatus according to the manufacturer's instructions, and immunoblotted with the indicated antibodies as described previously [14] . All blots were developed using enhanced chemiluminescence (Amersham Life Sciences, Cleveland, OH, U.S.A.).
Microscopy
For immunofluorescence studies, cells on glass coverslips were fixed with 3.2 % (v/v) paraformaldehyde in PBS and processed as described previously [14] using the monoclonal anti-TCPTP antibody CF4, either on its own or in combination with a polyclonal antibody specific for the protein phosphorylated on Ser-304 (see Supplementary Figure 1 at http://www.BiochemJ.org/ bj/380/bj3800939add.htm). Alternatively, cells were stained with polyclonal anti-TCPTP 159 antibodies in combination with the monoclonal anti-(cyclin B1) antibody. Alexa Fluor 488 or 568 goat anti-mouse or anti-rabbit IgGs were used as secondary antibodies (Molecular Probes, Eugene, OR, U.S.A.). For staining of DNA, cells were incubated with 5 µg/ml RNAase (Roche Diagnostics, Indianapolis, IN, U.S.A.) in PBS for 30 min, incubated with either propidium iodide or TOTO-3 (Molecular Probes) in PBS containing RNAase for 15 min, and then washed extensively with PBS. Where indicated, nuclei were visualized with Hoechst stain. Coverslips were mounted on to glass slides in DAKO ® fluorescent mounting medium (DAKO Corp., Carpinteria, CA, U.S.A.), and immunofluorescence was visualized on an Olympus BX60 microscope or a Bio-Rad MRC 1024 confocal microscope.
Protein kinase and phosphatase assays
CDK assays
For assessing CDK-mediated phosphorylation of Ser-304 in vitro, recombinant TCPTP-(1-349) and the corresponding Ser-304 phosphorylation site mutant [TCPTP-(1-349)S304E] were utilized rather than full-length TCPTP because of ease of expression and purification. These proteins were expressed in bacteria and purified by ion-exchange chromatography as described previously [23] . The CDK/cyclin proteins were prepared and purified as described previously [28] . Phosphorylations were undertaken in CDK assay buffer (20 mM Hepes, pH 7.0, 1 mM DTT, 10 mM MgCl 2 , 10 mM NaF, 1 mM sodium vanadate and 10 mM β-glycerophosphate) in the presence of 100 µM ATP (plus 5 µCi of [γ -
32 P]ATP) with or without 10 µg of TCPTP-(1-349) or TCPTP-(1-349)S304E, in the presence or absence of 15 units of the indicated CDK/cyclin proteins, in a total volume of 30 µl for 30 min at 37
• C {1 unit is defined as 1 pmol of phosphate transferred/min per µg of glutathione S-transferasepRb-(773-928) substrate at 37
• C [28] }. Reactions were terminated by the addition of 15 µl of 3 × Laemmli sample buffer, boiled for 5 min and then resolved by SDS/PAGE and analysed by Coomassie Blue staining and autoradiography.
Polo-like kinase Plk1 assays
Aliquots of 5 µg of dephosphorylated α-casein (Sigma) or 7 µg of TC45-(1-349) or TC45-(1-349)S304E were incubated with 0.75 µg of purified recombinant Plk1 in kinase buffer (50 mM Tris, pH 7.7, 10 mM MgCl 2 , 2 mM EGTA, 5 mM DTT, 0.5 mM sodium vanadate, 5 mM NaF and 0.1 µM okadaic acid) in the presence of 25 µM ATP (plus 10 µM [γ -
32 P]ATP) with or without 50 µM roscovitine in a total volume of 40 µl for 30 min at 30
• C. Reactions were terminated by the addition of 20 µl of hot 3 × Laemmli sample buffer, boiled for 5 min and then resolved by SDS/PAGE and analysed by Coomassie Blue staining and autoradiography.
PTP assays HEK293 cells were electroporated as described previously [15] with 5 µg of TC45-R222M-pCG, TC45-pCG or TC45-S304A-pCG, and at 24 h post-transfection cells were treated with 100 ng/ ml nocodazole for an additional 20 h. Cells were then homogenized (Dounce homogenizer; 20 strokes) in ice-cold hypotonic lysis buffer (20 mM Tris, pH 7.5, 5 mM KCl, 1.5 mM MgCl 2 , 2 mM EGTA, 5 µg/ml leupeptin, 1 µg/ml pepstatin, 1 mM benzamidine, 2 mM PMSF, 1 µM okadaic acid and 50 nM calyculin A) and clarified by centrifugation (100 000 g, 20 min, 4
• C). DTT was added to the supernatants to a final concentration of 1 mM before PTP activity was assayed. RCML (reduced carboxyamidomethylated and maleylated lysozyme) or MBP (myelin basic protein) was phosphorylated with the baculovirally expressed protein tyrosine kinase domain of the human insulin receptor [29] . PTP activity was measured as described previously [23] using 10-20 µM tyrosine-phosphorylated 32 P-labelled RCML or MBP at 30
• C for 10-20 min in reaction buffer containing 25 mM imidazole, pH 7.2, 5 mM EDTA, 1 mM DTT and 1 mg/ml BSA. No more than 10-20 % of the substrate was dephosphorylated in each reaction.
RESULTS
Identification of TCPTP phosphorylation sites
Previous studies have indicated that TCPTP can be phosphorylated in a cellular context [30] . To identify phosphorylation sites on TCPTP, asynchronous COS1 cells overexpressing TC45 were labelled with [ 32 P]P i for 5 h. The overexpressed and 32 Plabelled TC45 was immunoprecipitated, resolved by SDS/PAGE and digested in situ with trypsin. The 32 P-labelled tryptic phosphopeptides were then extracted from the polyacrylamide gel, achieving approx. 98 % recovery of 32 P. First, the extracted [ 32 P]phosphopeptides were separated in two dimensions by high-voltage electrophoresis and TLC, revealing two apparently distinct phosphopeptides (A and B) ( Figure 1A ). When the two phosphopeptides were extracted from the cellulose plates and analysed for their phosphoamino acid content, both contained 32 P-labelled phosphoserine ( Figure 1B) ; 32 P-labelled phosphothreonine and phosphotyrosine were not detected even in total TC45 tryptic digests (results not shown). These results indicate that TC45 may be phosphorylated exclusively on serine in asynchronous cells.
Next, the extracted [ 32 P]phosphopeptides were purified by reverse-phase chromatography, and [
32 P]phosphopeptide-containing fractions were identified by Cerenkov counting ( Figure 1C) Figure 1E ), consistent with phosphorylation of Ser-304.
Our results indicated that, in asynchronous COS1 cells, ectopically expressed TC45 was phosphorylated on Ser-304. To determine the extent of Ser-304 phosphorylation relative to other potential TC45 phosphorylation sites, Ser-304 was mutated to alanine (TC45-S304A) and the phosphorylation state of TC45-S304A was compared with that of wild-type TC45 (Figure 2 ). COS1 cells expressing TC45 or TC45-S304A transiently were labelled with [ 32 P]P i , and incorporation into immunoprecipitated TC45 and TC45-S304A was monitored by autoradiography. Mutation of Ser-304 inhibited the phosphorylation of TC45 in asynchronous cells by as much as 90 % (Figure 2 ). In contrast, mutation of Ser-298 to Ala had no significant effect on 32 P incorporation into TC45 (results not shown). These results indicate that ectopic TC45 is phosphorylated predominantly on Ser-304 in asynchronous cells.
Endogenous TC45, but not TC48, is phosphorylated on Ser-304
Since the Ser-304 phosphorylation site was identified using ectopic TC45, we could not exclude the possibility that phosphorylation may have occurred due to TC45 overexpression. To assess the phosphorylation of endogenous TCPTP on Ser-304, we immunoprecipitated endogenous TCPTP from COS1 cells transfected with the pMT2 vector control using the anti-TCPTP antibody CF4 ( Figure 3A) ; we also immunoprecipitated TCPTP from ) was covalently attached on to a Sequelon-AA TM (PerSeptive Biosystems) membrane and subjected to phosphate-release sequencing on a Hewlett Packard protein sequencer as described in the Materials and methods section. Radiolabelled PTC-amino acids in fractions were monitored by spotting on to a silica plate followed by PhosphorImager analysis and quantified using Image-Quant software (Molecular Dynamics).
TC45-and TC45-S304A-overexpressing cells using the same antibody to serve as immunoblot controls for the Ser-304 phosphorylation-specific antibody ( Figure 3A) . The TCPTP immunoprepitates were divided in two, resolved by SDS/PAGE and immunoblotted either with affinity-purified polyclonal antibodies specific for TCPTP phosphorylated on Ser-304 (see Supplementary Figure 1 at http://www.BiochemJ.org/bj/380/ bj3800939add.htm) or with affinity-purified polyclonal anti-TCPTP 159 antibodies (see Supplementary Figure 1 ) (Figure 3A) . Despite endogenous TC48 and TC45 being present COS1 cells were transfected with constructs for the expression of TC45 or TC45-S304A. Transfected COS1 cells were labelled with [ 32 P]P i (2 h with 1 mCi/10 cm dish), and radiolabelled TCPTP was immunoprecipitated, resolved by SDS/PAGE and analysed by Coomassie Blue staining. 32 P incorporation into the immunoprecipitated TC45 or the TC45-S304A mutant was monitored on a Phosphorimager and quantified using Image-Quant software (Molecular Dynamics). 32 P incorporation was normalized for TCPTP protein and expressed as percentage incorporation compared with wild-type TC45.
Figure 3 TC45, but not TC48, is phosphorylated on Ser-304
(A) COS1 cells were transfected with the pMT2 vector control or constructs for the expression of TC45 or the TC45-S304A mutant. TCPTP immunoprecipitates were resolved by SDS/PAGE and immunoblotted with affinity-purified polyclonal antibodies specific for the TCPTP phosphorylated on Ser-304 (Phos-TCPTP) or affinity-purified polyclonal TCPTP 159 antibodies (see Supplementary Figure 1 at http://www.BiochemJ.org/bj/380/bj3800939add.htm). Indicated are the endogenous TC48 and TC45 proteins in the vector control immunoprecipitates. (B) COS1 cells were transfected using the calcium phosphate precipitation method as described previously [14] with 200 ng of pMT2 vector control, TC45-pMT2 or TC48-pMT2. At 24 h post-transfection, cells were collected in 3 × Laemmli sample buffer and lysates were resolved by SDS/PAGE and immunoblotted with the monoclonal anti-TCPTP antibody CF4, and then reprobed with polyclonal Phos-TCPTP antibodies.
in equal amounts in immunoprecipitates from vector controltransfected cells, only endogenous TC45 was phosphorylated to any appreciable extent on Ser-304 ( Figure 3A) . Consistent with this, TC48 was phosphorylated poorly in comparison with TC45 when low amounts of the TCPTP variants were overexpressed in COS1 cells ( Figure 3B ). These results demonstrate (1) that phosphorylation of Ser-304 is not an artefact of overexpression, but instead that Ser-304 phosphorylation may be a physiologically relevant event, and (2) that phosphorylation of Ser-304 may be specific to TC45 in vivo.
Phosphorylation of TC45 occurs in a cell cycle-dependent manner and is optimal in mitosis
We next examined the circumstances under which Ser-304 phosphorylation may occur. We found that diverse stress-inducing agents, such as hyperosmotic shock (600 mM, 30 Figure 4A , left panel), caused a significant increase in Ser-304 phosphorylation and retarded the electrophoretic mobility of TC45 ( Figure 4A , right panel; see also Supplementary Figure 1 at http://www.BiochemJ. org/bj/380/bj3800939add.htm). A similar increase in the phosphorylation of Ser-304 was observed when cells were arrested in mitosis with the microtubule-stabilizing agent colcemid (results not shown). These results indicate that Ser-304 phosphorylation may be cell cycle-dependent.
To examine further the phosphorylation status of Ser-304 during cell cycle progression, CV1 cells expressing ectopic TC45 were accumulated at the G 1 /S transition (thymidine block) and released into G 2 , mitosis (M) and subsequently G 1 of the next cell cycle ( Figure 4B ). Cell cycle progression was monitored by assessing DNA content as measured by FACS and by assessing cyclin B1 protein levels; cyclin B1 levels are low in G 1 , then increase in G 2 , peaking at metaphase of mitosis; the protein is degraded at anaphase of mitosis, when sister chromatids segregate and cell division ensues [31] . Between 5 and 7 h after release from the G 1 /S block, the majority of cells had a 4n DNA content and increased expression of cyclin B1, consistent with cells being in late G 2 or M phase ( Figure 4B ). After 8 h of release, the proportion of cells with a 4n DNA content had declined, coinciding with a dramatic loss of cyclin B1 protein, consistent with cells exiting mitosis ( Figure 4B ). Ser-304 phosphorylation was low for the first 6 h, but increased dramatically at 7 h ( Figure 4B ). This delay in phosphorylation relative to the increase in cells with 4n DNA and cyclin B1 protein indicates that Ser-304 phosphorylation may occur late in G 2 and in mitosis. Ser-304 phosphorylation declined at 8 h, correlating with cyclin B1 loss and mitotic exit (Figure 4B) . Consistent with these results, fluorescence microscopy of asynchronous HEK293 cells expressing ectopic TC45 indicated that Ser-304 phosphorylation was optimal in mitotic cells, but absent in cells undergoing cytokinesis ( Figure 4C) .
Finally, to assess whether Ser-304 phosphorylation may occur in late G 2 prior to the onset of mitosis, HEK293 cells expressing TC45 or the TC45-S304A mutant as a control were treated with the DNA double-strand-break-inducing agent adriamycin, which arrests cells at the G 2 /M checkpoint by activating the ATR (ataxia telangiectasia-related)/Chk1 protein kinase signalling cascade [32] . The phosphorylation state of TC45 in response to adriamycin was monitored by assessing the electrophoretic mobility of TC45 and comparing it with that of TC45 in asynchronous cells or cells arrested in mitosis by overnight treatment with nocodazole ( Figure 5 ). Treatment of HEK293 cells with adriamycin resulted in the accumulation of a G 2 /M cell population (4n DNA content), consistent with G 2 /M checkpoint activation ( Figure 5A , upper panels), but did not alter the electrophoretic mobility of TC45 significantly when compared with asynchronous cells ( Figure 5A , lower panels). In contrast, nocodazole caused an increase in electrophoretically retarded ( Figure 5A , lower panels) and phosphorylated (see Supplementary Figure 1 at http://www.BiochemJ.org/bj/380/bj3800939add.htm) TC45. To assess further whether Ser-304 phosphorylation may occur at the G 2 /M checkpoint, we compared Ser-304 phosphorylation in cells accumulated at G 1 /S (thymidine block) with that in cells that had been released for 4, 7 or 12 h, or otherwise released for 4 h and then treated for another 12 h with adriamycin to arrest cells at the G 2 /M checkpoint ( Figure 5B) . Consistent with the results in Figures 4 and 5(A) , Ser-304 phosphorylation increased significantly in mitotic cells 7 h after release from G 1 /S, but not in cells arrested at the G 2 /M checkpoint with adriamycin (Figure 5B) . Taken together, these results indicate that TC45 Ser-304 phosphorylation may be restricted to the mitotic phase of the cell cycle. 
Phosphorylation of Ser-304 does not modulate TC45 activity
Previous studies have shown that the non-catalytic C-terminus of TC45 can suppress TC45 activity through a yet to be defined autoinhibitory mechanism [23] . Phosphorylation of Ser-304 may alter intrasteric interactions to modulate TC45 activity [23] . To ascertain whether this might be the case, we examined first whether the phosphatase activity of TC45 was increased in (A) HEK293 cells were transfected with constructs for the expression of a phosphatasedead TC45-R222M control or wild-type TC45 (WT). At 24 h post-transfection, cells were left untreated or treated for 20 h with 100 ng/ml nocodazole (Noc). (B) HEK293 cells transfected with constructs for the expression of TC45-R222M, wild-type TC45 (Wt) or TC45-S304A were treated with 100 ng/ml Noc for 20 h. Cells in (A) and (B) were homogenized in hypotonic lysis buffer and clarified by centrifugation as described in the Materials and methods section. PTP activity in supernatants was measured using tyrosine-phosphorylated 32 P-labelled MBP as substrate. The experiments shown are representative of at least three independent experiments with triplicate transfections assayed in duplicate. PTP activity was normalized for the overexpressed TCPTP protein in the corresponding supernatants. In (B), a representative immunoblot of supernatants from wild-type TC45-or TC45-S304A-expressing cells that were resolved extensively by SDS/PAGE (16 cm long gels; see the Materials and methods section) is shown; the electrophoretic mobilities of the phosphorylated and dephosphorylated forms of TC45 are indicated.
mitotic cells (Figure 6 ) where Ser-304 phosphorylation was optimal (Figure 4 ). We measured PTP activity in lysates from HEK293 cells transfected with constructs for the expression of wild-type TC45 or the catalytically inactive TC45-R222M mutant ( Figure 6A) . Asynchronous cells or nocodazole-treated metaphase-arrested cells were homogenized in hypotonic lysis buffer and PTP activity measured using tyrosine-phosphorylated RCML (results not shown) or MBP ( Figure 6A ) as substrate. We found no significant difference in TC45 activity in lysates from metaphase-arrested cells where TC45 was largely phosphorylated, as compared with asynchronous cells where TC45 was predominantly dephosphorylated ( Figure 6A) . Next, we compared the activity of TC45 with that of the S304A mutant from nocodazole-treated metaphase-arrested cells ( Figure 6B ). Mutation of Ser-304 and ablation of phosphorylation had no significant effect on phosphatase activity ( Figure 6B ) under conditions where phosphorylation of wild-type TC45, as determined by its retarded electrophoretic mobility relative to TC45-S304A (see Supplementary Figure 1 ), was stoichiometric ( Figure 6B, inset) . Taken together, these results indicate that phosphorylation of Ser-304 may not alter the phosphatase activity of TC45.
Phosphorylation of Ser-304 is mediated by CDKs
The Ser-304 phosphorylation site of TC45 is followed immediately by a proline residue (AFDHS 304 P) and conforms to the consensus recognition sequence for two classes of protein kinases: the MAPKs (mitogen-activated protein kinases) and the CDKs. In addition, the Ser-304 site (AFDHS 304 P) may also conform to the consensus site for phosphorylation by the Polo-like kinase Plk1 ([E/D]X[S/T]) [33] . All three protein kinases are essential for mitotic progression [34] [35] [36] [37] . Since a variety of cellular stresses failed to modulate the phosphorylation status of Ser-304 (results not shown), we surmised that stress-activated MAPKs such as c-Jun N-terminal kinase and p38 were unlikely to phosphorylate Ser-304. To examine the possible contribution of the MAPKs ERK1/2 to Ser-304 phosphorylation, TC45-expressing COS1 cells were treated with PD98059, a specific pharmacological inhibitor of ERK1/2 activation. Although PD98059 inhibited completely the activation of ERK1/2, it had no effect on TC45 Ser-304 phosphorylation, even after overnight treatment ( Figure 7A ). These results demonstrate that Ser-304 phosphorylation is independent of ERK1/2 activity.
To examine whether the phosphorylation of Ser-304 may be mediated by CDKs, TC45-expressing HEK293 cells were treated with roscovitine, a specific pharmacological inhibitor of CDKs 1, 2 and 5 (inhibits mammalian cellular proliferation with an average IC 50 of 16 µM) [38] . Treatment with roscovitine inhibited almost completely the phosphorylation of Ser-304 (Figure 7B) . Furthermore, treatment of TC45-overexpressing cells with another specific CDK inhibitor, SU9516 (inhibits G 2 /M progression at concentrations of approx. 12.5-25 µM) [39] , also suppressed Ser-304 phosphorylation ( Figure 7C ). Taken together, these results indicate that CDKs may phosphorylate TC45 in vivo. Consistent with this, we found that recombinant CDKs could phosphorylate the Ser-304 site directly in vitro ( Figure 8A) . Although, the recombinant CDKs could also phosphorylate other site(s) on TCPTP-(1-349), the stoichiometry of these in vitro phosphorylation events was significantly lower ( Figure 8A ). In contrast, Plk1 activity was not inhibited by roscovitine in vitro, indicating that Plk1 is unlikely to phosphorylate Ser-304 in vivo. Moreover, Plk1 could not phosphorylate TCPTP either on Ser-304 or on other sites under conditions where phosphorylation of the heterologous substrate α-casein was robust ( Figure 8B ). Taken together, these results indicate that CDKs may mediate the phosphorylation of TC45 on Ser-304 in vivo.
DISCUSSION
Mitosis is morphologically the most dynamic phase of the cell cycle, and a large number of events are co-ordinated temporally and spatially by reversible protein phosphorylation [31, 34] . In the present study we have identified Ser-304 as a major phosphorylation site in the ubiquitous tyrosine phosphatase TCPTP. We have generated phosphorylation-specific antibodies and demonstrated that Ser-304 phosphorylation occurs in mitosis and is mediated by CDKs. CDKs phosphorylate a wide array of substrates regulating cell cycle progression [31, 34, 40] . Different CDKs act to regulate different stages of the cell cycle, with CDK4/cyclin D activity being optimal in G 1 , CDK2/cyclin E at the G 1 /S transition, CDK2/cyclin A at the G 2 /M transition and CDK1/cyclin B1 in mitosis [31, 34] . Although all CDKs tested phosphorylated Ser-304 efficiently in vitro, phosphorylation of Ser-304 was optimal as cells progressed into mitosis, and subsided upon mitotic exit, consistent with phosphorylation being mediated by either CDK1/ cyclin B1 or CDK2/cyclin A in vivo. Whereas CDK2/cyclin A is important for S-phase progression and the G 2 /M transition, CDK1/cyclin B1 is essential for mitotic entry and regulates mitotic processes such as nuclear envelope breakdown, centrosome separation, spindle assembly, chromosome separation and mitotic exit [34] . CDK2/cyclin A activity increases steadily from S phase and peaks at the G 2 /M transition, but decreases as cells proceed into mitosis. In contrast, CDK1/cyclin B is activated at the G 2 /M transition and peaks in mitosis [31, 34] , but induction of the G 2 /M checkpoint prevents CDK1 activation and mitotic entry [31, 34] . Since Ser-304 phosphorylation did not occur in response to G 2 /M checkpoint activation by adriamycin, our studies indicate that Ser-304 may be phosphorylated by CDK1/cyclin-B1 in vivo.
Whereas the phosphorylation of dual-specificity Cdc25 phosphatases by CDKs to regulate mitotic progression is well documented [41, 42] , evidence for phosphorylation of tyrosinespecific PTPs by CDKs in vivo has been somewhat scant. TCPTP and PTP1B are highly related phosphatases and share an overall sequence identity of 65 % (72 % identity and 86 % similarity within the catalytic domain) [1] . PTP1B is phosphorylated in mitosis on two Ser-Pro sites [43] that are not present in TCPTP. Only one of these two PTP1B Ser-Pro sites can serve as an efficient site for phosphorylation by CDKs in vitro [43] . Moreover, the phosphorylation of PTP1B on both sites also occurs in response to cellular stresses, in particular osmotic shock, independent of cell cycle stage and MAPK activation [44] . In contrast, phosphorylation of TCPTP on Ser-304 was not induced by cellular stresses such as osmotic shock, indicating that TCPTP and PTP1B may be phosphorylated by distinct protein kinases in vivo.
In contrast with the Cdc25 phosphatases, where phosphorylation on different sites by CDKs and other protein kinases can regulate subcellular localization and activity [31, 41, 42, 45] , phosphorylation of TCPTP on Ser-304 had no apparent effect on TC45 activity. In addition, we observed no apparent role for Ser-304 phosphorylation in controlling TC45 localization (see Supplementary Figure 2 at http://www.BiochemJ.org/bj/ 380/bj3800939add.htm). Mutation of Ser-304 to alanine or glutamic acid did not alter the nucleocytoplasmic distribution of TC45 in response to mitogens such as EGF or to cellular stresses such as hyperosmotic shock (results not shown) that induce the cytoplasmic accumulation of TC45 [12] , and we observed no significant difference in localization in G 1 , G 2 or mitotic cells (see Supplementary Figure 2 ). In addition, in mitotic cells, where Ser-304 phosphorylation was optimal, the localization of TC45 phosphorylated on Ser-304, as monitored with our phosphorylation-specific antibodies, was similar to that of total TC45 monitored with the monoclonal anti-TCPTP antibody CF4 (results not shown). Furthermore, when nuclei from TC45-overexpressing HeLa cells were fractionated into soluble, chromatin and nuclear matrix-associated proteins, TC45 was detected in the soluble and nuclear matrix fractions, but not in chromatin fractions, and mutation of Ser-304 to Ala had no significant effect on this distribution (results not shown). Similarly, phosphorylation of Ser-304 did not alter TC45 protein stability, as assessed by [ 35 S]methionine pulse-chase experiments comparing wild-type TC45 and the Ser-304 phosphorylation site mutants (see Supplementary Figure 2 ). In the case of Cdc25, a recent paper by Bulavin et al. [42] has shown that dual phosphorylation of Ser-214 and Ser-216 controls localization and mitotic progression. Whereas phosphorylation of Cdc25C on Ser-216 allows for 14-13-3 binding and nuclear exclusion, preventing CDK1 activation prior to mitosis, phosphorylation on Ser-214 prevents phosphorylation on Ser-216 and 14-13-3 binding, making cells unresponsive to DNA damage and ensuring that CDK1 remains active once mitosis is initiated [42] . Our studies indicate that the Ser-304 site is the major site of phosphorylation in human TCPTP in randomly growing cells, and the major site of CDK-mediated phosphorylation in vitro. However, we cannot exclude the possibility that other steadystate phosphorylation sites may exist, or that other sites may be phosphorylated in response to specific stimuli, and that, together with Ser-304 phosphorylation, these may regulate TC45. In line with this possibility, we observed low levels of 32 P incorporation in the TC45-S304A mutant, but the physiological significance of such low-level incorporation in overexpressed TC45 remains unclear.
Although the Ser-304 site is conserved in the porcine orthologue of human TCPTP, rats lack the sequence corresponding to residues 296-314 and mice lack the proline residue immediately following Ser-304 [4] . Therefore the Ser-304 CDK site is not conserved in rodents. However, it is possible that other sites may be phosphorylated in place of Ser-304; consistent with this, a previous study has reported that rat TCPTP is phosphorylated in mitosis on a yet to be identified site, and that this phosphorylation event retards TC45's electrophoretic mobility [30] . Hence the functional outcome of phosphorylation on Ser-304 of human TCPTP in mitosis might be conserved in different species.
A recent study from the laboratory of David Shalloway [46] has indicated that PTPα-mediated c-Src activation in mitosis is regulated by protein kinase C-dependent phosphorylation of PTPα. Whereas the catalytic activity of PTPα towards non-specific substrates such as tyrosine-phosphorylated MBP is suppressed only slightly when the protein kinase C phosphorylation sites are mutated to Ala, activity towards the physiological substrate c-Src is abrogated completely, demonstrating that Ser/Thr phosphorylation of a PTP can regulate substrate specificity [46] . Therefore, although mutating Ser-304 to Ala had no significant effect on TC45 activity towards non-physiological substrates such as tyrosine-phosphorylated RCML and MBP, we cannot exclude the possibility that Ser-304 phosphorylation may regulate activity towards a physiologically relevant mitotic substrate. Although very early studies on TCPTP had indicated that expression of the TCPTP catalytic domain in baby hamster kidney cell lines could induce cytokinetic failure and multinucleation [47] , mitotic substrates for TCPTP remain unknown.
In the present study we have observed differential mitotic phosphorylation of human TC48 and TC45 on Ser-304, suggesting that the TCPTP variants might have distinct functions during cell division. Our studies identify Ser-304 as a major TCPTP phosphorylation site and the TC45 variant as a potential mediator of CDK1/cyclin B1 processes in mitosis.
